@article{4b7d603385db4265b9ba4232f53aeb51,
title = "Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity",
abstract = "Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.",
author = "Boris Engels and Engelhard, {Victor H.} and John Sidney and Alessandro Sette and Binder, {David C.} and Liu, {Rebecca B.} and Kranz, {David M.} and Meredith, {Stephen C.} and Rowley, {Donald A.} and Hans Schreiber",
note = "Funding Information: We thank Dr. Theodore Karrison (The University of Chicago) for help with statistical analysis, Zhang Yi for generating the cancer lines MC57-hgp100 and MC57-mgp100, Andrea Schietinger for the pMFG-(SIY) 3 -Cerulean vector, Andrew Hawk for peptide synthesis, and the University of Chicago Flow Cytometry Core Facility. We also thank Ainhoa Arina and Christian Idel for critical review of the manuscript. This work was supported by a Research Fellowship of the DFG EN 703/3-1 (to B.E.); NIH grants P01-CA97296 (to D.M.K. and H.S.), R01-CA22677, and R01-CA37156 (to H.S.); a grant from the Melanoma Research Alliance (to D.M.K.), and the Cancer Center at the University of Chicago. ",
year = "2013",
month = apr,
day = "15",
doi = "10.1016/j.ccr.2013.03.018",
language = "English (US)",
volume = "23",
pages = "516--526",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}